{"pmid":32342677,"title":"Severe Thrombocytopenia in a Patient with COVID-19.","text":["Severe Thrombocytopenia in a Patient with COVID-19.","Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.","Infect Chemother","Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran","32342677"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered."],"journal":"Infect Chemother","authors":["Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342677","source":"PubMed","week":"202018|Apr 27 - May 03","keywords":["covid-19","ceftriaxone, levofloxacin","lopinavir/ritonavir","thrombocytopenia"],"locations":["Thrombocytopenia"],"e_drugs":["Ceftriaxone","lopinavir-ritonavir drug combination","Levofloxacin"],"topics":["Case Report"],"weight":1,"_version_":1665351883894554625,"score":8.574329,"similar":[{"pmid":32302435,"title":"Thrombocytopenia and Its Association with Mortality in Patients with COVID-19.","text":["Thrombocytopenia and Its Association with Mortality in Patients with COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100 - 150] or (150 - ) group after taking the unit (x 10(9/L) ) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5% and 4.7% for (0, 50], (50, 100], (100 - 150] and (150 - ) group, respectively. With (150 - ) as the reference, nadir platelet counts of (100 - 150], (50, 100] and (0, 50] group had a relative risk of 3.42 (95% CI 2.36 - 4.96), 9.99 (95% CI 7.16 - 13.94) and 13.68 (95% CI 9.89 - 18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count is, the higher the mortality becomes.","J Thromb Haemost","Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You","32302435"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100 - 150] or (150 - ) group after taking the unit (x 10(9/L) ) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5% and 4.7% for (0, 50], (50, 100], (100 - 150] and (150 - ) group, respectively. With (150 - ) as the reference, nadir platelet counts of (100 - 150], (50, 100] and (0, 50] group had a relative risk of 3.42 (95% CI 2.36 - 4.96), 9.99 (95% CI 7.16 - 13.94) and 13.68 (95% CI 9.89 - 18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count is, the higher the mortality becomes."],"journal":"J Thromb Haemost","authors":["Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302435","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14848","keywords":["covid-19","sars-cov-2","generalized linear model","mortality","thrombocytopenia"],"source":"PubMed","topics":["NONE","Diagnosis"],"weight":1,"locations":["Thrombocytopenia","Jinyintan Hospital","Wuhan","China","thrombocytopenia","Thrombocytopenia","Thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664635401263906816,"score":283.81412},{"pmid":32178975,"pmcid":"PMC7102663","title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","text":["Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31 x 10(9)/L; 95% CI, from -35 to -29 x 10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48 x 10(9)/L; 95% CI, -57 to -39 x 10(9)/L. In the four studies (n = 1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.","Clin Chim Acta","Lippi, Giuseppe","Plebani, Mario","Henry, Brandon Michael","32178975"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31 x 10(9)/L; 95% CI, from -35 to -29 x 10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48 x 10(9)/L; 95% CI, -57 to -39 x 10(9)/L. In the four studies (n = 1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization."],"journal":"Clin Chim Acta","authors":["Lippi, Giuseppe","Plebani, Mario","Henry, Brandon Michael"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178975","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.cca.2020.03.022","keywords":["coronavirus, covid-19","platelets","thrombocytopenia"],"source":"PubMed","topics":["Mechanism"],"weight":1,"locations":["thrombocytopenia","Medline","Scopus","thrombocytopenia","Thrombocytopenia"],"_version_":1664640874618814465,"score":252.53296},{"pmid":32296910,"title":"Mechanism of thrombocytopenia in COVID-19 patients.","text":["Mechanism of thrombocytopenia in COVID-19 patients.","Since December 2019, a novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. Some studies reported cases of thrombocytopenia, but hardly any studies mentioned how the virus causes thrombocytopenia. We propose several mechanisms by which coronavirus disease 2019 causes thrombocytopenia to better understand this disease and provide more clinical treatment options.","Ann Hematol","Xu, Panyang","Zhou, Qi","Xu, Jiancheng","32296910"],"abstract":["Since December 2019, a novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. Some studies reported cases of thrombocytopenia, but hardly any studies mentioned how the virus causes thrombocytopenia. We propose several mechanisms by which coronavirus disease 2019 causes thrombocytopenia to better understand this disease and provide more clinical treatment options."],"journal":"Ann Hematol","authors":["Xu, Panyang","Zhou, Qi","Xu, Jiancheng"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296910","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00277-020-04019-0","keywords":["coronavirus disease 2019","platelet","severe acute respiratory syndrome coronavirus 2","thrombocytopenia"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China","thrombocytopenia","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664641388256428032,"score":215.20293},{"pmid":32317225,"title":"A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report.","text":["A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report.","INTRODUCTION: An ongoing outbreak of a novel coronavirus disease (coronavirus disease 2019, COVID-19) has become a global threat. While clinical reports from China to date demonstrate that the majority of cases remain relatively mild and recover with supportive care, it is also crucial to be well prepared for severe cases warranting intensive care. Initiating appropriate infection control measures may not always be achievable in primary care or in acute-care settings. CASE: A 45-year-old man was admitted to the intensive care unit due to severe pneumonia, later confirmed as COVID-19. His initial evaluation in the resuscitation room and treatments in the intensive care unit was performed under droplet and contact precaution with additional airborne protection using the N95 respirator mask. He was successfully treated in the intensive care unit with mechanical ventilation and extracorporeal membrane oxygenation for respiratory support; and antiretroviral treatment with lopinavir/ritonavir. His total intensive care unit stay was 15 days and was discharged on hospital day 24. CONCLUSIONS: Strict infection control precautions are not always an easy task, especially under urgent care in an intensive care unit. However, severe cases of COVID-19 pneumonia, or another novel infectious disease, could present at any moment and would be a continuing challenge to pursue appropriate measures. We need to be well prepared to secure healthcare workers from exposure to infectious diseases and nosocomial spread, as well as to provide necessary intensive care.","J Infect Chemother","Nakamura, Kazuha","Hikone, Mayu","Shimizu, Hiroshi","Kuwahara, Yusuke","Tanabe, Maki","Kobayashi, Mioko","Ishida, Takuto","Sugiyama, Kazuhiro","Washino, Takuya","Sakamoto, Naoya","Hamabe, Yuichi","32317225"],"abstract":["INTRODUCTION: An ongoing outbreak of a novel coronavirus disease (coronavirus disease 2019, COVID-19) has become a global threat. While clinical reports from China to date demonstrate that the majority of cases remain relatively mild and recover with supportive care, it is also crucial to be well prepared for severe cases warranting intensive care. Initiating appropriate infection control measures may not always be achievable in primary care or in acute-care settings. CASE: A 45-year-old man was admitted to the intensive care unit due to severe pneumonia, later confirmed as COVID-19. His initial evaluation in the resuscitation room and treatments in the intensive care unit was performed under droplet and contact precaution with additional airborne protection using the N95 respirator mask. He was successfully treated in the intensive care unit with mechanical ventilation and extracorporeal membrane oxygenation for respiratory support; and antiretroviral treatment with lopinavir/ritonavir. His total intensive care unit stay was 15 days and was discharged on hospital day 24. CONCLUSIONS: Strict infection control precautions are not always an easy task, especially under urgent care in an intensive care unit. However, severe cases of COVID-19 pneumonia, or another novel infectious disease, could present at any moment and would be a continuing challenge to pursue appropriate measures. We need to be well prepared to secure healthcare workers from exposure to infectious diseases and nosocomial spread, as well as to provide necessary intensive care."],"journal":"J Infect Chemother","authors":["Nakamura, Kazuha","Hikone, Mayu","Shimizu, Hiroshi","Kuwahara, Yusuke","Tanabe, Maki","Kobayashi, Mioko","Ishida, Takuto","Sugiyama, Kazuhiro","Washino, Takuya","Sakamoto, Naoya","Hamabe, Yuichi"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317225","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jiac.2020.03.018","keywords":["coronavirus disease 2019 (covid-19)","extracorporeal membrane oxygenation (ecmo)","infection control","intensive care","lopinavir/ritonavir","respiratory failure"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["China","Tokyo","Japan"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination"],"_version_":1664815087711420417,"score":214.14264},{"pmid":32314010,"title":"Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","text":["Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.","Rheumatol Int","Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho","32314010"],"abstract":["In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications."],"journal":"Rheumatol Int","authors":["Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314010","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00296-020-04584-7","keywords":["covid-19","coronavirus","disease-modifying antirheumatic drugs","pneumonia","rheumatoid arthritis"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine"],"_version_":1664714520041357312,"score":204.19267}]}